OBJECTIVE: Previous studies have found that family-focused treatment is an effective adjunct to pharmacotherapy in stabilizing symptoms in adult bipolar disorder. The authors examined whether pharmacotherapy and family-focused treatment for adolescents with bipolar disorder was more effective than pharmacotherapy and brief psychoeducation (enhanced care) in decreasing time to recovery from a mood episode, increasing time to recurrence, and reducing symptom severity over 2 years. METHOD: A total of 145 adolescents (mean age, 15.6 years) with bipolar I or II disorder and a DSM-IV-TR manic, hypomanic, depressive, or mixed episode in the previous 3 months were randomly assigned, with family members, either to pharmacotherapy and family-focused treatment, consisting of psychoeducation (i.e., recognition and early intervention with prodromal symptoms), communication enhancement training, and problem-solving skills training, delivered in 21 sessions over 9 months; or to pharmacotherapy and three weekly sessions of enhanced care (family psychoeducation). Independent evaluators assessed participants at baseline, every 3 months during year 1, and every 6 months during year 2, using weekly ratings of mood. RESULTS: Twenty-two participants (15.2%) withdrew shortly after randomization. Time to recovery or recurrence and proportion of weeks ill did not differ between the two treatment groups. Secondary analyses revealed that participants in family-focused treatment had less severe manic symptoms during year 2 than did those in enhanced care. CONCLUSIONS: After an illness episode, intensive psychotherapy combined with best-practice pharmacotherapy does not appear to confer advantages over brief psychotherapy and pharmacotherapy in hastening recovery or delaying recurrence among adolescents with bipolar disorder.
RCT Entities:
OBJECTIVE: Previous studies have found that family-focused treatment is an effective adjunct to pharmacotherapy in stabilizing symptoms in adult bipolar disorder. The authors examined whether pharmacotherapy and family-focused treatment for adolescents with bipolar disorder was more effective than pharmacotherapy and brief psychoeducation (enhanced care) in decreasing time to recovery from a mood episode, increasing time to recurrence, and reducing symptom severity over 2 years. METHOD: A total of 145 adolescents (mean age, 15.6 years) with bipolar I or II disorder and a DSM-IV-TR manic, hypomanic, depressive, or mixed episode in the previous 3 months were randomly assigned, with family members, either to pharmacotherapy and family-focused treatment, consisting of psychoeducation (i.e., recognition and early intervention with prodromal symptoms), communication enhancement training, and problem-solving skills training, delivered in 21 sessions over 9 months; or to pharmacotherapy and three weekly sessions of enhanced care (family psychoeducation). Independent evaluators assessed participants at baseline, every 3 months during year 1, and every 6 months during year 2, using weekly ratings of mood. RESULTS: Twenty-two participants (15.2%) withdrew shortly after randomization. Time to recovery or recurrence and proportion of weeks ill did not differ between the two treatment groups. Secondary analyses revealed that participants in family-focused treatment had less severe manic symptoms during year 2 than did those in enhanced care. CONCLUSIONS: After an illness episode, intensive psychotherapy combined with best-practice pharmacotherapy does not appear to confer advantages over brief psychotherapy and pharmacotherapy in hastening recovery or delaying recurrence among adolescents with bipolar disorder.
Authors: David J Miklowitz; Michael W Otto; Ellen Frank; Noreen A Reilly-Harrington; Stephen R Wisniewski; Jane N Kogan; Andrew A Nierenberg; Joseph R Calabrese; Lauren B Marangell; Laszlo Gyulai; Mako Araga; Jodi M Gonzalez; Edwin R Shirley; Michael E Thase; Gary S Sachs Journal: Arch Gen Psychiatry Date: 2007-04
Authors: Roy H Perlis; Melissa P Delbello; Sachiko Miyahara; Stephen R Wisniewski; Gary S Sachs; Andrew A Nierenberg Journal: Biol Psychiatry Date: 2005-09-28 Impact factor: 13.382
Authors: M Tohen; S M Strakowski; C Zarate; J Hennen; A L Stoll; T Suppes; G L Faedda; B M Cohen; P Gebre-Medhin; R J Baldessarini Journal: Biol Psychiatry Date: 2000-09-15 Impact factor: 13.382
Authors: Tina R Goldstein; Wonho Ha; David A Axelson; Benjamin I Goldstein; Fangzi Liao; Mary Kay Gill; Neal D Ryan; Shirley Yen; Jeffrey Hunt; Heather Hower; Martin Keller; Michael Strober; Boris Birmaher Journal: Arch Gen Psychiatry Date: 2012-11
Authors: Boris Birmaher; David Axelson; Benjamin Goldstein; Michael Strober; Mary Kay Gill; Jeffrey Hunt; Patricia Houck; Wonho Ha; Satish Iyengar; Eunice Kim; Shirley Yen; Heather Hower; Christianne Esposito-Smythers; Tina Goldstein; Neal Ryan; Martin Keller Journal: Am J Psychiatry Date: 2009-05-15 Impact factor: 18.112
Authors: David J Miklowitz; David A Axelson; Boris Birmaher; Elizabeth L George; Dawn O Taylor; Christopher D Schneck; Carol A Beresford; L Miriam Dickinson; W Edward Craighead; David A Brent Journal: Arch Gen Psychiatry Date: 2008-09
Authors: David J Miklowitz; Christopher D Schneck; Patricia D Walshaw; Amy S Garrett; Manpreet K Singh; Catherine A Sugar; Kiki D Chang Journal: Early Interv Psychiatry Date: 2017-08-04 Impact factor: 2.732
Authors: Lisa A Pan; Tina R Goldstein; Brian T Rooks; Mary Hickey; Jie Yu Fan; John Merranko; Kelly Monk; Rasim S Diler; Dara J Sakolsky; Danella Hafeman; Satish Iyengar; Benjamin Goldstein; David J Kupfer; David A Axelson; David A Brent; Boris Birmaher Journal: J Clin Psychiatry Date: 2017-03 Impact factor: 4.384
Authors: Christopher D Schneck; Kiki D Chang; Manpreet K Singh; Melissa P DelBello; David J Miklowitz Journal: J Child Adolesc Psychopharmacol Date: 2017-07-21 Impact factor: 2.576
Authors: Benjamin I Goldstein; Tina R Goldstein; Katelyn A Collinger; David A Axelson; Oscar G Bukstein; Boris Birmaher; David J Miklowitz Journal: J Psychiatr Pract Date: 2014-05 Impact factor: 1.325
Authors: Lisa A O'Donnell; Marc J Weintraub; Alissa J Ellis; David A Axelson; Robert A Kowatch; Christopher D Schneck; David J Miklowitz Journal: Fam Process Date: 2020-02-03
Authors: Joan Rosenbaum Asarnow; Martha C Tompson; Alexandra M Klomhaus; Kalina Babeva; David A Langer; Catherine A Sugar Journal: J Child Psychol Psychiatry Date: 2019-12-15 Impact factor: 8.982
Authors: Martha C Tompson; Catherine A Sugar; David A Langer; Joan R Asarnow Journal: J Am Acad Child Adolesc Psychiatry Date: 2017-04-07 Impact factor: 8.829
Authors: Lisa A O'Donnell; Alissa J Ellis; Margaret M Van de Loo; Jonathan P Stange; David A Axelson; Robert A Kowatch; Christopher D Schneck; David J Miklowitz Journal: J Affect Disord Date: 2018-04-09 Impact factor: 4.839
Authors: Martine Vallarino; Chantal Henry; Bruno Etain; Lillian J Gehue; Craig Macneil; Elizabeth M Scott; Angelo Barbato; Philippe Conus; Stefanie A Hlastala; Mary Fristad; David J Miklowitz; Jan Scott Journal: Lancet Psychiatry Date: 2015-05-27 Impact factor: 27.083